The short version of anti-doping analysis fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-24. Anything still debated is marked as such rather than presented as settled.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
To expose the sensory tube feet and the eyespot to external stimuli, some starfish turn up the tips of their arms while moving. Having descended from bilateral organisms, starfish may move in a bilateral fashion, particularly when hunting or threatened. When crawling, certain arms act as the leading arms, while others trail behind. When a starfish finds itself upside down, two adjacent arms and an opposite arm press against the ground to lift up the two remaining arms; the opposite arm leaves the ground as the starfish turns over and recovers its normal stance. Apart from their function in locomotion, the tube feet act as accessory gills. The water vascular system serves to transport oxygen from, and carbon dioxide to, the tube feet and nutrients from the gut to the muscles involved in locomotion. Fluid movement is bidirectional and initiated by cilia.
== Legacy == The popular image of the sans-culotte has gained currency as an enduring symbol for the passion, idealism and patriotism of the common man of the French Revolution. The term sans-culottism, sans-culottisme in French, refers to this idealized image and the themes associated with it. Many public figures and revolutionaries who were not strictly working class styled themselves citoyens sans-culottes in solidarity and recognition. However, in the period immediately following the Thermidorian Reaction, the sans-culottes and other far-left political factions were heavily persecuted and repressed by the likes of the Muscadins. The French Republican Calendar at first termed the complementary days at the end of the year Sansculottides; however, the National Convention suppressed the name when adopting the Constitution of the Year III (1795) and substituted the name jours complémentaires ("additional days").
Kastl has made appearances in the blockbuster films Hulk and War of the Worlds. Kastl had a recurring role on Scrubs for 8 years from 2001 to 2009 as Dr. Doug Murphy, the totally incompetent doctor who finally finds his calling as a very competent forensic pathologist. However, he asked to be allowed to "sit out" the fourth season of Scrubs as he had broken both his heels in a ski jumping accident. This was written into the show to keep the character around and, as described on the DVD commentary by creator Bill Lawrence, "We felt that breaking both of his feet was a very 'Doug' thing to do, so we decided to write it into the show." He had a recurring role, as FBI agent Todd Jaracki, for the single season of Patrick Swayze's The Beast (2009).
==== Denervation supersensitivity ==== When the innervation to Substance P nerve terminals is lost, post-synaptic cells compensate for the loss of adequate neurotransmitter by increasing the expression of post-synaptic receptors. This, ultimately, leads to a condition known as denervation supersensitivity as the post-synaptic nerves will become hypersensitive to any release of Substance P into the synaptic cleft.
Sources: en.wikipedia.org
The SADC has specifically emphasised the importance of combating non-traditional maritime threats as part of the 2050 Integrated Maritime Strategy. The Bay of Bengal Initiative for Multi-Sectoral Technical and Economic Cooperation (BIMSTEC), has enabled the states within the Bay of Bengal to create greater maritime security through collaboration between countries. Furthermore, BIMSTEC has launched a Convention on Cooperation in Combating International Terrorism, Organised Crime and Illicit Drug Trafficking. This facilitates regional cooperation specific to the illicit drug trade, and provides the region with the foundations to develop their response further. The existing regional and individual responses by states have, in practice, been limited to seizure-based responses. This is due to gaps in the current legal infrastructure, which prevent effective prosecution of smugglers following drug seizures. Huge drug seizures have been made by both the Combined Maritime Forces (CMF) and the Combined task force (CTF), such as when the CTF successfully seized 6.2 tonnes of hashish over two days. However, gaps in the current laws prevent further action. One such example is Article 110 of the UNSC Law of the Sea Convention 1982, which does not include a suspicion of drug smuggling as a legitimate reason to board a vessel without gaining permission from the ship’s flagged country. This has decreased the amount of possible seizures, and gaining permission to board vessels is complicated by insufficient regional cooperation within the criminal justice system.
=== Blood glucose === Postprandial blood glucose levels become lower after consumption of a meal containing β-glucan as a result of increased gut viscosity, which delays gastric emptying and lengthens travel through the small intestine. In one review, the net decrease in blood glucose absorption reduced postprandial blood insulin concentrations, improving insulin sensitivity. A 2021 meta-analysis of clinical trials concluded that oat beta-glucan with molecular weights greater than 300 kg/mol reduced incremental area-under-the-curve by 23%, peak blood glucose by 28%, and insulin by 22% in a dose-responsive fashion, with similar results in participants with or without diabetes. Diabetic people who increased their daily consumption of beta-glucans by more than 3 grams per day for months also lost body weight.
The election was keenly contested; the democratic republicans adopted as their candidate Ledru-Rollin, the "pure republicans" Cavaignac, and the recently reorganized Imperialist party Prince Louis-Napoléon Bonaparte. Unknown in 1835, and forgotten or despised since 1840, Louis Napoleon had in the last eight years advanced sufficiently in the public estimation to be elected to the Constituent Assembly in 1848 by five departments. He owed this rapid increase of popularity partly to blunders of the government of July, which had unwisely aroused the memory of the country, filled as it was with recollections of the Empire, and partly to Louis Napoléon's campaign carried on by means of pamphlets of socialistic tendencies. Moreover, the monarchists, led by Thiers and the committee of the Rue de Poitiers, were no longer content even with the safe dictatorship of the upright Cavaignac, and joined forces with the Bonapartists. On 10 December the peasants gave over 5,000,000 votes to a name: Napoléon, which stood for order at all costs, against 1,400,000 for Cavaignac. Henri Georges Boulay de la Meurthe was elected vice president, a unique position in French history.
Sources: en.wikipedia.org
== Function == The target of C5 convertase is complement protein C5. C5 is a two-chain (α, β) plasma glycoprotein (Mr = 196,000). C5 and C3 have similar structure. However, C5 does not appear to contain the internal thiol ester group reported for C3 and C4. C5 has relatively few disulfide bonds. There are three disulfide bonds in C5a, the α-chain has 15 half-Cystines, and the β-chain has only 6 half-Cystines. This comparatively low level of stabilizing disulfide bridges may provide a partial explanation for the irreversible conformational change imparted on C5 after cleavage to C5a and C5b. In addition, the relatively low number of disulfide bonds could account for instability of C5 when exposed to chaotropic agents such as potassium thiocyanate. Electron micrographs of negatively stained C5 indicate that the protein is irregular in shape and contains several lobes. First of all, C5 has to bind to C3b fragment. The capacity to bind C3b is a stable feature of component C5, as C5b also has this binding capacity. The C5 convertase selectively cleaves an Arginyl-Leucine peptide bond at position 74-75 in the α-chain (Mr = 116,000) of C5. Research has shown that during the classical pathway of the complement system, an inactive A6 allotype of c4 completely stalls the molecules' ability to act as a c5 binding subunit1. This defect in C4A6 activity happens during the C5 binding step to the 4b and c3b complex. α´-chain (Mr, = 105,000) and the activation peptide, C5a, is formed, while β-chain (Mr = 80,000) remains unchanged.
In March 2006, then-senator Barack Obama said when he voted against raising the debt ceiling: "The fact that we are here today to debate raising America's debt limit is a sign of leadership failure." By the end of Bush's presidency, unemployment climbed to 7.2%.
The name protein that he propose for the organic oxide of fibrin and albumin, I wanted to derive from [the Greek word] πρωτειος, because it appears to be the primitive or principal substance of animal nutrition. Mulder went on to identify the products of protein degradation such as the amino acid, leucine, for which he found a (nearly correct) molecular weight of 131 Da.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.